ArticleBMC gastroenterology2026
Exploring the link between Mycobacterium avium subsp. Paratuberculosis and colorectal cancer development.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) ranks third in incidence and fourth in cancer-related mortality worldwide. It typically begins as benign polyps that may progress to malignancy through cumulative genetic alterations. Inflammatory bowel disease (IBD) is a major risk factor for CRC, and Mycobacterium avium subspecies paratuberculosis (MAP) has been implicated in its pathogenesis and may also contribute to CRC development, particularly in regions with MAP-infected livestock.
methodsIn this case-control study which included 147 participants, we analyzed 74 patients with colorectal conditions, encompassing both precancerous and cancerous types, alongside 73 healthy controls (HCs). The Participants underwent colonoscopy at a clinical center in Golestan province, and provided informed consent and relevant health data. Exclusion criteria included recent antibiotic use and a history of gastrointestinal disease. Genomic DNA was extracted from intestinal mucus samples and analyzed using nested PCR.
resultsIn our study, the prevalence of MAP was significantly higher in precancerous (46.7%) and cancerous patients (57.1%) compared to HCs (13.3%, p < 0.0001), suggesting a possible association with disease progression that warrants further investigation.
conclusionThe study highlights a strong association between MAP and colorectal neoplasia, especially in patients with precancerous and cancerous conditions. Despite no notable differences in lifestyle factors between groups, MAP's prevalence points to its potential influence on CRC progression. This warrants further investigation into MAP's role in CRC, particularly in regions with MAP-infected livestock, for public health insights and prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.